Drug therapies for osteoporosis and application of stem cells in bone regeneration medicine: the current and future

doi:10.3969/j.issn.2095-4344.2015.19.026

Abstract

Abstract:

BACKGROUND: Besides drug therapy, regenerative therapy is now a matter of global interest in treating osteoporosis. Therefore, it is also important to find better candidate cells.
OBJECTIVE: To cognize the status of drug therapies for osteoporosis and stem cells as regenerative therapy.
METHODS: A computer-based search of PubMed was performed by the first author to retrieve articles relevant to stem cell therapy for osteoporosis published from January 2000 to December 2014. The keywords were “osteoporosis, drug therapy, bone regenerative medicine, stem cell therapy”, which appeared in the title, abstract or keywords, and the relevant references were also looked up. Articles published recently or in authoritative journals were preferred, and finally 39 articles were included in result analysis.
RESULTS AND CONCLUSION: Yoshikazu Mikami and co-workers from Japan found two novel bone formation accelerators, SST-VEDI and SSH-BMI, which provides a new direction for related studies on drug therapy. Due to
the osteogenesis ability, lack of ethical controversy and less damage, de-differentiated fat cells and pulp stem cells may be promising candidate cells for bone regeneration medicine.

Key words: Osteoporosis, Bone Regeneration, Stem Cells, Drug Therapy

CLC Number:

R318

Lin Yuan, Tao Shu-qing. Drug therapies for osteoporosis and application of stem cells in bone regeneration medicine: the current and future[J]. Chinese Journal of Tissue Engineering Research, 2015, 19(19): 3107-3111.

Figures/Tables 2

References

[1] Schaffler MB, Kennedy OD. Osteocyte signaling in bone. Curr Osteoporos Rep. 2012;10(2):118-125.
[2] Kular J, Tickner J, Chim SM, et al. An overview of the regulation of bone remodelling at the cellular level. Clin Biochem. 2012;45(12):863-873.
[3] Lippuner K.The future of osteoporosis treatment - a research update. Swiss Med Wkly. 2012;142:w13624.
[4] McClung M, Harris ST, Miller PD, et al. Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am J Med. 2013;126(1):13-20.
[5] Rizzoli R, Reginster JY. Adverse drug reactions to osteoporosis treatments. Expert Rev Clin Pharmacol. 2011;4(5):593-604.
[6] Ruggiero SL, Mehrotra B. Bisphosphonate-related osteonecrosis of the jaw: diagnosis, prevention, and management. Annu Rev Med. 2009;60:85-96.
[7] Bagan J, Scully C, Sabater V, et al. Osteonecrosis of the jaws in patients treated with intravenous bisphosphonates (BRONJ): A concise update. Oral Oncol. 2009;45(7):551-554.
[8] Kikuiri T, Kim I, Yamaza T, et al. Cell-based immunotherapy with mesenchymal stem cells cures bisphosphonate-related osteonecrosis of the jaw-like disease in mice. J Bone Miner Res. 2010;25(7):1668-1679.
[9] Esbrit P, Alcaraz MJ. Current perspectives on parathyroid hormone (PTH) and PTH-related protein (PTHrP) as bone anabolic therapies. Biochem Pharmacol. 2013;85(10): 1417-1423.
[10] Morley P, Whitfield JF, Willick GE. Parathyroid hormone: an anabolic treatment for osteoporosis. Curr Pharm Des. 2001; 7(8):671-687.
[11] Black DM, Greenspan SL, Ensrud KE, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med. 2003;349(13): 1207-1215.
[12] Finkelstein JS, Hayes A, Hunzelman JL, et al. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med. 2003;349(13):1216-1226.
[13] Lombardi G, Di Somma C, Rubino M, et al. The roles of parathyroid hormone in bone remodeling: prospects for novel therapeutics. J Endocrinol Invest. 2011;34(7 Suppl):18-22.
[14] Drake MT, Srinivasan B, Mödder UI, et al. Effects of intermittent parathyroid hormone treatment on osteoprogenitor cells in postmenopausal women. Bone. 2011;49(3):349-355.
[15] Lowe H, McMahon DJ, Rubin MR, et al. Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype. J Clin Endocrinol Metab. 2007;92(8): 3001-3005.
[16] Komrakova M, Stuermer EK, Werner C, et al. Effect of human parathyroid hormone hPTH (1-34) applied at different regimes on fracture healing and muscle in ovariectomized and healthy rats. Bone. 2010;47(3):480-492.
[17] Subbiah V, Madsen VS, Raymond AK, et al. Of mice and men: divergent risks of teriparatide-induced osteosarcoma. Osteoporos Int. 2010;21(6):1041-1045.
[18] Mikami Y, Somei M, Takagi M. A tryptamine derivative, SST-VEDI-1, inhibits apoptosis and stimulates mineralization in osteoblasts. Endocr J. 2009;56(5):665-678.
[19] Mikami Y, Somei M, Tsuda H. SSH-BM-I, a tryptamine derivative, stimulates mineralization in terminal osteoblast differentiation but inhibits osteogenesis of pre-committed progenitor cells. J Pharmacol Sci. 2011;116(1):63-72.
[20] Somei M. Definitions of IPF and APF. Heterocycles. 2004; 64(1):483.
[21] Somei M, Iwaki T, Yamada F, et al.The ideal synthetic method aimed at the leads for an a2-BLOCKR, an inhibitor of blood platelet aggregation, and an anti-osteoporosis agent. Heterocycles. 2006;68(1):1565-1569.
[22] Mikami Y, Senoo M, Lee M, et al. Inhibitory effects of a tryptamine derivative on ultraviolet radiation-induced apoptosis in MC3T3-E1 mouse osteoblasts. J Pharmacol Sci. 2011;115(2):214-220.
[23] Ichioka N, Inaba M, Kushida T, et al. Prevention of senile osteoporosis in SAMP6 mice by intrabone marrow injection of allogeneic bone marrow cells. Stem Cells. 2002;20(6): 542-551.
[24] Schwartz SD, Hubschman JP, Heilwell G, et al. Embryonic stem cell trials for macular degeneration: a preliminary report. Lancet. 2012;379(9817):713-720.
[25] Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126(4):663-676.
[26] Moad M, Pal D, Hepburn AC, et al. A novel model of urinary tract differentiation, tissue regeneration, and disease: reprogramming human prostate and bladder cells into induced pluripotent stem cells. Eur Urol. 2013;64(5):753-761.
[27] Vitale AM, Wolvetang E, Mackay-Sim A. Induced pluripotent stem cells: a new technology to study human diseases. Int J Biochem Cell Biol. 2011;43(6):843-846.
[28] Zhang G, Shang B, Yang P, et al. Induced pluripotent stem cell consensus genes: implication for the risk of tumorigenesis and cancers in induced pluripotent stem cell therapy. Stem Cells Dev. 2012;21(6):955-964.
[29] Matsumoto T, Kano K, Kondo D, et al. Mature adipocyte- derived dedifferentiated fat cells exhibit multilineage potential. J Cell Physiol. 2008;215(1):210-222.
[30] Yagi K, Kondo D, Okazaki Y, et al. A novel preadipocyte cell line established from mouse adult mature adipocytes. Biochem Biophys Res Commun. 2004;321(4):967-974.
[31] Oki Y, Watanabe S, Endo T, et al. Mature adipocyte-derived dedifferentiated fat cells can trans-differentiate into osteoblasts in vitro and in vivo only by all-trans retinoic acid. Cell Struct Funct. 2008;33(2):211-222.
[32] Kazama T, Fujie M, Endo T, et al. Mature adipocyte-derived dedifferentiated fat cells can transdifferentiate into skeletal myocytes in vitro. Biochem Biophys Res Commun. 2008; 377(3): 780-785.
[33] Sakuma T, Matsumoto T, Kano K, et al. Mature, adipocyte derived, dedifferentiated fat cells can differentiate into smooth muscle-like cells and contribute to bladder tissue regeneration. J Urol. 2009;182(1):355-365.
[34] Jumabay M, Matsumoto T, Yokoyama S, et al. Dedifferentiated fat cells convert to cardiomyocyte phenotype and repair infarcted cardiac tissue in rats. J Mol Cell Cardiol. 2009;47(5):565-575.
[35] Ohta Y, Takenaga M, Tokura Y, et al. Mature adipocyte-derived cells, dedifferentiated fat cells (DFAT), promoted functional recovery from spinal cord injury-induced motor dysfunction in rats. Cell Transplant. 2008;17(8): 877-886.
[36] Nur R, Fukuda N, Matsumoto T, et al. Implantation of dedifferentiated fat cells ameliorates habu snake venom-induced chronic renal dysfunction in tenascin-C- deficient mice. Nephron Exp Nephrol. 2008;110(3):e91-98.
[37] Gronthos S, Mankani M, Brahim J, et al. Postnatal human dental pulp stem cells (DPSCs) in vitro and in vivo. Proc Natl Acad Sci U S A. 2000;97(25):13625-13630.
[38] Miura M, Gronthos S, Zhao M, et al. SHED: stem cells from human exfoliated deciduous teeth. Proc Natl Acad Sci U S A. 2003;100(10):5807-5812.
[39] Tamaoki N, Takahashi K, Tanaka T, et al. Dental pulp cells for induced pluripotent stem cell banking. J Dent Res. 2010;89(8): 773-778.